F-Term-List

A61K38/00-38/58;41/00-45/08;48/00;50/00,100;51/00,100;51/02,100;51/04,100;51/04,310;51/06,100;51/08,100;51/10,100;51/12,100

AA00
TYPE OF INVENTION

AA01

AA02

AA03

AA06

AA07

. Medicinal inventions e.g. proteins or lipoids

. . with description of specific uses

. . with description of specific medicinal preparations or formulation methods

. Process inventions e.g. methods for producing proteins or lipoids

. Material inventions e.g. proteins or lipoids

AA11

AA12

AA13

AA14

AA16

AA17

AA18

AA19

AA20

. Medicinal inventions containing substances treated by wave energy or particle radiation

. Medicinal inventions containing radioactive materials

. Medicinal inventions containing gene therapy or genetic substances

. Medicinal invention containing an immunological preparation that stimulates the reticuloendothelial system.

. Medicinal inventions containing active ingredients that are not chemically specified

. . One active ingredient

. . Two active ingredients

. . . One unspecified active ingredient

. . . Two unspecified active ingredients

AA21

AA22

AA23

AA24

AA25

AA27

AA30

. . Three or more active ingredients

. . . One unspecified active ingredient

. . . Two unspecified active ingredients

. . . Three or more unspecified active ingredients

. . Active ingredients bound to each other

. Medicinal inventions containing unspecified active ingredients or auxiliary components

. Others (*)

A61K38/00-38/58

BA00
CHEMICAL STRUCTURE

BA01

BA02

BA03

BA04

BA05

BA07

BA08

BA09

BA10

. Full-length amino acid sequence being identified

. Partial amino acid sequence being identified

. Amino acid sequence being unknown

. . Amino acid composition being known

. . characterised by physical and chemical properties

. Structural components of peptide chains

. . comprising L- alpha-amino acids only

. . comprising D-alpha-amino acids

. . comprising amino acids other than alpha-amino acids

BA11

BA13

BA14

BA15

BA16

BA17

BA18

BA19

BA20

. characterised by three-dimensional structures of peptide chains

. Number of alpha-amino acids composing peptide chains

. . Two

. . Three

. . Four to five

. . Six to ten

. . Eleven to twenty three

. . Twenty four to fifty

. . Fifty one to one hundred

BA21

BA22

BA23

BA24

BA25

BA26

BA27

BA28

. . One hundred one to one hundred fifty

. . One hundred fifty-one or greater

. Linear peptides

. Peptides having rings consisting only of peptide bonds

. Containing rings consisting of peptide bonds and bonds other than the peptide bonds.

. . Disulfide (S-S) bonds

. . Ester bonds

. . Amide bonds

BA31

BA32

BA33

BA34

BA35

BA36

BA37

BA38

. with characteristic structural components

. . Heterocyclic compounds

. . Compounds containing boron silicon phosphorus arsenic or metals

. . Sugars or polysaccharides

. . Nucleotides or nucleic acids

. . Steroids or lipids

. . Macromolecular compounds

. . Pigments

BA41

BA42

BA43

BA44

BA46

BA47

BA48

BA50

. being bound with other proteins

. binding to carriers

. Hydrolysates

. specified with functional names but not described with chemical structures

. Lipoids

. . Phospholipids

. . Glycolipids

. Others (*)

CA00
ORIGIN

CA01

CA03

CA04

CA05

CA07

CA09

. Viruses

. Fungi or lichens

. . Bacteria or actinomycetes

. . Eumycetes including mushrooms fungi or yeasts

. Algae

. Moss including moss hepaticae or anthocerotae

CA11

CA13

CA14

CA15

CA17

CA18

CA19

CA20

. Protozoa including ameba or paramecium

. Plants

. . Grains including rice barley or corn

. . Beans

. Mammals

. . Humans

. . Monkeys

. . Bovine

CA21

CA22

CA23

CA25

CA26

CA27

CA28

CA29

CA30

. . Porcine

. . Sheep

. . Mice or rats

. . Organs tissues or cells

. . . Blood cells or lymphocytes

. . . Tumours

. . . Nerves or brains

. . . Placentae or uterus

. . . Urinary organs

CA31

CA32

CA33

CA34

CA35

CA36

CA37

CA38

CA39

. . . Kidneys

. . . Pancreas

. . . Livers

. . . Bones or bone marrow

. . Body fluids

. . . Blood plasma blood serum or lymphatic fluids

. . . Amniotic fluids

. . . Milk

. . . Urine

CA41

CA43

CA45

CA47

CA49

. Birds

. Reptiles or amphibians

. Fish

. Shellfishes

. Insects

CA51

CA53

CA56

CA59

. Other animals

. Gene recombinant cells

. Cultured cells and tissues

. Synthetic origins

CA62

CA70

. Unspecified or indefinite origins

. Others (*)

DA00
BIOPHYLACTIC FUNCTION-RELATED PROTEIN

DA01

DA02

DA03

DA04

DA05

DA06

DA07

DA08

DA09

DA10

. Cytokines

. . Macrophage activating factors

. . Tuftsin

. . Macrophage migratory factors

. . Macrophage migration-inhibiting factors

. . Thymic hormones

. . . Thymosin

. . . Killer T-cell activating factors

. . . Suppresser T-cell induction factors

. . . Substances for suppressing T-cell deoxyribonucleic acid (DNA) synthesis

DA11

DA12

DA13

DA14

DA15

DA16

DA17

DA18

DA19

DA20

. . Cyclosporin

. . Interleukin

. . . Interleukin 1

. . . Interleukin 2

. . . Interleukin 3

. . . Interleukin-4

. . . Interleukin 5

. . . Interleukin 6

. . Colony-stimulating factors

. . Muramyl dipeptides

DA21

DA22

DA23

DA24

DA25

DA26

DA27

DA28

DA29

DA30

. . Interferon

. . . Alpha-interferon

. . . Beta-interferon

. . . Gamma-interferon

. . tumour-necrosis factors

. . Lymphotoxins

. Anti-tumour proteins

. . Bleomycin

. . Anticancer drugs

. . Cell aggregation substances

DA31

DA32

DA33

DA34

DA35

DA36

DA37

DA38

DA39

DA40

. . . Lectins

. . Toxins

. . . Toxins from cells

. . . Toxins produced by plants

. . . Toxins produced by animals

. Albumin

. . Blood serum albumin

. Globulin

. . Immunoglobulin

. Extracellular matrix proteins

DA41

DA42

DA43

DA44

DA45

DA46

DA47

DA48

DA50

. Peptidic antibacterial substances

. . Linear peptide antibacterial substances

. . Cyclic peptide antibacterial substances

. . . Vancomycin antibiotics

. Cytokine receptors

. . Interleukin receptors

. . . Interleukin 1 receptors

. . . Interleukin 2 receptors

. . Alpha-interferon receptors

DA51

DA52

DA53

DA58

DA59

DA60

. . Beta-interferon receptors

. . Gamma-interferon receptors

. . tumour necrosis factor receptors

. Cytokine antagonists

. . Interleukin antagonists

. . Interferon antagonists

DB00
HORMONE-ASSOCIATED PROTEIN

DB01

DB02

DB03

DB04

DB05

DB06

DB07

DB08

DB09

DB10

. Hormones

. . Natriuretic peptide

. . Hypothalamic hormones

. . . Opioidpeptides

. . . . Dynorphins

. . . . Endorphins

. . . . Enkephalins

. . . Thyroid-stimulating hormones and thyroid-emission hormones

. . . Luteinising hormone-releasing hormone

. . . Gonadotropin-releasing hormones

DB11

DB12

DB13

DB14

DB15

DB16

DB17

DB18

DB19

DB20

. . . Somatostatins

. . . Adrenocorticotrophic hormone-releasing factors

. . . . Neurotensins

. . . Growth hormone-releasing factors

. . . Chromatophore stimulating hormone-releasing factors

. . . Chromatophorotropic hormone release-suppressing factors

. . . Prolactin releasing factors

. . . Prolactin release-suppressing factors

. . . Head-activators

. . Pituitary hormones

DB21

DB22

DB23

DB24

DB25

DB26

DB27

DB28

DB29

DB30

. . . Adrenocorticotropic hormones

. . . Growth hormones

. . . Prolactin

. . . Thyroid-stimulating hormones

. . . Luteinising hormones

. . . Follicle-stimulating hormones

. . . Chromatophore stimulating hormones

. . . Oxytocin

. . . Vasopressin

. . Thyroid hormones

DB31

DB32

DB33

DB34

DB35

DB36

DB37

DB38

DB39

DB40

. . . Calcitonine

. . Parathormones

. . Pancreatic hormones

. . . Insulin

. . . Glucagon

. . . Pancreatic polypeptides

. . Alimentary-canal hormones

. . . Secretin

. . . Vasoactive intestinal polypeptides

. . . Gastric inhibitory polypeptides

DB41

DB42

DB43

DB44

DB45

DB46

DB47

DB48

DB49

DB50

. . . Gastrin

. . . Gastrin-releasing peptides

. . . Cholesystokinin

. . . Motirin

. . . Cerulein

. . . Urogastrone

. . Salivary-gland hormones

. . Placental hormones

. . . Choriogonadotropin

. . . Placental lactogen

DB51

DB52

DB53

DB54

DB55

DB56

DB57

DB58

DB59

DB60

. . Ovarian hormones

. . Growth factors

. . . Epidermal growth factors

. . . Fibroblast growth factors

. . . Blood platelet growth factors

. . . Erithropoietin

. . . Blood vessel forming factors

. . . Insulin-like growth factors

. . . Nerve growth factors

. . . Osteogenesis promoting factors

DB61

DB62

DB63

DB64

DB65

DB66

DB70

. . . Tumour growth factors

. . . Liver-cell growth factors

. Hormone receptors

. . Opioid receptors

. . Erithropoietin receptors

. . Prolactin receptors

. Hormone antagonists

DB71

DB72

DB73

DB74

DB75

DB76

DB77

DB78

DB79

DB80

. . Luteinising hormone-releasing hormone antagonists

. . Thyroid-stimulating hormone releasing hormone antagonists

. . Vasopressin antagonists

. . Angiotensin II antagonists

. . Opioid antagonists

. . Cholecystokinin antagonists

. . Sodium diuretic peptide antagonists

. . Oxytocin antagonists

. . Gastrin releasing peptide antagonists

. . Corticotropin releasing factor antagonists

DC00
ENZYME RELATED PROTEINACEOUS MATERIAL: OTHER FUNCTIONAL PROTEINS

DC01

DC02

DC03

DC04

DC05

DC06

DC07

DC08

DC09

DC10

. Enzymes

. . Proteolytic enzymes

. . . Serine protease

. . . . Kallikrein

. . . . Urokinase

. . . . Plasmin

. . . Thiol protease

. . . Carboxyl protease

. . . Metallic protease

. . Blood coagulation factors

DC11

DC12

DC13

DC14

DC15

DC16

DC17

DC18

DC19

DC20

. . . Blood coagulation factor I

. . . Blood coagulation factor II

. . . Blood coagulation factor III

. . . Blood coagulation factor VII

. . . Blood coagulation factor VIII

. . . Blood coagulation factor IX

. . . Blood coagulation factor X

. . . Blood coagulation factor XI

. . . Blood coagulation factor XII

. . . Blood coagulation factor XIII

DC21

DC22

DC23

DC24

DC25

DC26

DC27

DC28

DC29

DC30

. . Plasminogen activating factor

. . Hydrolase not covered by DC02 to DC21

. . Oxidoreductase

. . . Superoxide dismutase

. . Transferase

. . Lyase

. . Isomerase

. . Ligase

. . Enzyme mixtures

. Coenzymes

DC31

DC32

DC33

DC34

DC35

DC36

DC37

DC38

DC39

DC40

. . Glutathione

. Enzyme inhibitors

. . Encephalinase inhibitors

. . Trypsin inhibitors

. . Thorombin inhibitors

. . Plasmin inhibitors

. . Renin inhibitors

. . Pepsin inhibitors

. . Collagenase inhibitors

. . Angiotensin converting enzyme inhibitors

DC41

DC42

DC43

DC44

DC50

. . Elastase inhibitors

. . Chymotrypsin inhibitors

. . Human immunodeficiency virus (HIV) protease inhibitors

. . Kallikrein inhibitors

. Others (*)

A61K38/00-38/58;41/00-45/08;48/00;50/00,100;51/00,100;51/02,100;51/04,100;51/04,310;51/06,100;51/08,100;51/10,100;51/12,100

MA00
COMPOUNDING AGENT, DOSAGE FORM, OR APPLICATION SITE

MA01

MA02

MA05

. Compounding agents

. . containing two or more types of active ingredients

. . characterised by non-active ingredients

MA11

MA12

MA13

MA16

MA17

. Dosage forms

. . Gaseous

. . . Aerosols or foaming agents

. . Liquids

. . . Solution agents i.e. aqueous or non-aqueous agents

MA21

MA22

MA23

MA24

MA27

MA28

. . . Dispersion agents

. . . . Emulsions

. . . . Syrups or suspension agents

. . . . Liposomes

. . Semisolids

. . . Creams pastes or ointments

MA31

MA32

MA34

MA35

MA36

MA37

MA38

. . . Suppositories or bougies

. . . Pasting agents

. . Solid

. . . Pills or buccals

. . . Pellets

. . . Capsules

. . . . Microcapsules

MA41

MA43

MA44

MA47

. . . Granular agents

. . . Powdered agents

. . . . Freeze-dried powders

. . . Gum

MA51

MA52

MA55

MA56

MA57

MA58

MA59

MA60

. Application sites

. . Oral application

. . Non-oral applications

. . . Body cavities or mucous membranes

. . . . Oral cavities

. . . . Eyes

. . . . Nasal cavities

. . . . Rectums

MA63

MA65

MA66

MA67

MA70

. . . Skin or skin exterior

. . . Blood vessels or tissue interior

. . . . Injection infusion or intravenous drips

. . . . Internal embedding

. Others (*)

NA00
PURPOSE OR EFFECT OF COMPOUND PER SE, COMPOUNDING OR FORMULATION

NA01

NA02

NA03

NA04

NA05

NA06

NA07

NA08

NA09

NA10

. Virus non-activation

. Solubilisation

. Stabilisation

. Preparation when in use

. Enhanced effects or improved selectivity of effects

. Reduction of side effects

. Reduced toxicity

. Painlessness

. Adjustment of taste or odour

. Change of the mode of dosage delivery

NA11

NA12

NA13

NA14

NA15

NA20

. Improvement of absorption

. Controlled release or continuation

. Drug delivery system (DDS )

. Revelation of new medicine effects

. Prodrugs

. Others (*)

ZA00
MEDICINAL USE OR TARGET ORGAN

ZA01

ZA02

ZA03

ZA04

ZA05

ZA06

ZA07

ZA08

. Pharmaceuticals acting on the nervous system

. . Medicines acting on central nervous system

. . . Central nervous system inhibitors

. . . . General anaesthetics

. . . . Hypnotics or tranquilizers

. . . . Anti-epilepsy drugs

. . . . Antipyretics

. . . . Pain-killers

ZA11

ZA12

ZA14

ZA15

ZA16

ZA18

ZA20

. . . Central nervous stimulants

. . . . Anti-depression drugs

. . . Drugs to prevent motion sickness

. . . Drugs for improvement of brain function

. . . . Drugs for treatment of Alzheimer's disease

. . . Anti-psychoneurosis medicines

. . acting on peripheral nerve systems

ZA21

ZA22

ZA23

ZA24

ZA25

ZA26

ZA27

ZA28

ZA29

ZA30

. . . Drugs for sensory nerves

. . . Drugs for motor nerves

. . . . Drugs for relaxation of skeletal muscle

. . . Autonomic nerve drugs

. . . . Sympathetic nerve stimulants

. . . . Sympathetic nerve inhibitors

. . . . Parasympathetic nerve stimulants

. . . . Parasympathetic nerve inhibitors

. . . . Antispasmodics

. . . . Diaphoretics or anhidrotics

ZA31

ZA32

ZA33

ZA34

ZA36

ZA37

ZA38

ZA39

ZA40

. Pharmaceuticals acting on each individual organ

. . Drugs for sensory organs

. . . Ophthalmic drugs

. . . Otorhinolaryngolonogical drugs

. . Drugs for circulatory organs

. . . Myocardium stimulants

. . . Myocardium inhibitors

. . . Vasodilators

. . . . Coronary vasodilators

ZA41

ZA42

ZA43

ZA44

ZA45

. . . Vasoconstrictors

. . . Hypotensive drugs

. . . Drugs for raising blood pressure

. . . Blood vessel reinforcing agents

. . . Drugs for atherosclerosis

ZA51

ZA52

ZA53

ZA54

ZA55

ZA59

ZA60

. . Pharmaceutical for hematogenous organs i.e. bone marrow blood or body fluids

. . . Blood substitute agents

. . . Hemostatics or blood coagulation agents

. . . Anti-coagulants or thrombus solution agents

. . . Anti-anemia drugs

. . Drugs for respiratory organs

. . . Respiratory stimulants

ZA61

ZA62

ZA63

ZA66

ZA67

ZA68

ZA69

ZA70

. . . Bronchus vasodilator

. . . Cough suppressant

. . . Expectorants

. . Pharmaceutical for digestive organs

. . . Dental-cavity drugs

. . . Drugs for peptic ulcer

. . . Drugs for peptic digestion

. . . Anti-obesity drugs

ZA71

ZA72

ZA73

ZA75

ZA76

ZA77

. . . Antiemetics or vomit-inducing drugs

. . . Laxatives

. . . Drugs for intestinal disorder

. . . Drugs for liver or bile duct system

. . . . Drugs for gall bladder

. . . . Gallstone-dissolving drugs

ZA81

ZA82

ZA83

ZA84

ZA85

ZA86

ZA89

ZA90

. . Drugs for urinogenital organs or anus

. . . Urinary-vessel bactericides

. . . Diuretics

. . . Anti-diuretics

. . . Drugs for uterine contractions

. . . Birth-control pills

. . Outer skin medicinal

. . . Sanitizers for outer skin

ZA91

ZA92

ZA94

ZA96

ZA97

. . . Skin-softeners

. . . Drugs for scalp or hair

. . Drugs for muscle systems

. . Drugs for skeletal structural systems

. . . Pharmaceutical for osteoporosis

ZB00
MEDICINAL USE OR BIOPHYLAXIS

ZB01

ZB02

ZB03

ZB05

ZB07

ZB08

ZB09

. Pharmaceuticals specified by the effects on biophylaxis mechanisms.

. . Pharmaceuticals for cellular immune systems

. . . Interferon-inducing agents

. . Drugs for the mechanism of humoral immunity (antibody production)

. . Drugs for immunoregulation

. . Drugs for immunosuppression

. . Immunity accelerators

ZB11

ZB13

ZB15

. . Inflammation drugs

. . Anti-allergy pharmaceuticals

. . Anti-rheumatism pharmaceuticals

ZB21

ZB22

ZB26

ZB27

. Pharmaceuticals acting on tissue cellular functions

. . Pharmaceuticals for cellular invigoration

. . Pharmaceuticals for tumours

. . . Anti-leukaemia agents

ZB31

ZB32

ZB33

ZB35

ZB37

ZB38

ZB39

. Pharmaceuticals acting on pathogenic organisms

. . Pharmaceuticals for pathogenic microorganisms

. . . Anti-viral drugs

. . . Antibacterial drugs

. . Drugs for parasites

. . . Anti-protozoan drugs

. . . Vermicides

ZC00
MEDICINAL USE, FUNCTION, MECHANISM, OBJECT, OR OTHERS

ZC01

ZC02

ZC03

ZC04

ZC06

ZC08

ZC10

. Pharmaceuticals specified with the effects on biofunctions

. . In vivo bioactive substance-like drugs

. . . Hormone-like agents

. . . . Pituitary hormone-like drugs

. . . . Thyroid or parathormone-like agents

. . . . Paranephros hormone-like drugs

. . . . Male hormone-like drugs

ZC11

ZC12

ZC13

ZC14

ZC16

ZC17

ZC19

ZC20

. . . . Female hormone-like agents

. . . Prostaglandin-like drugs

. . . Antihistamines

. . . Antiserotonins

. . . Bradykinin-like drugs

. . . Angiotensin-like drugs

. . . Enzyme activation or invigorative drugs

. . . Enzyme inhibitors

ZC21

ZC22

ZC23

ZC24

ZC25

ZC26

ZC28

ZC29

. . Drugs for metabolic system

. . . Vitamin-like drugs

. . . . Vitamin A or D-like agents

. . . . Vitamin B-like agents

. . . . . Vitamin B1-like agents

. . . . . Vitamin B2-like agents

. . . . Vitamin C or P-like agents

. . . . Vitamin E or K-like agents

ZC31

ZC33

ZC35

ZC37

ZC39

. . . Drugs for uric acid metabolic system

. . . Agents for lipid metabolic system

. . . Agents for carbohydrate metabolic system

. . . Detoxicants

. . . Pharmaceuticals for habit-forming toxication

ZC41

ZC42

ZC43

ZC44

ZC45

ZC48

ZC50

. Pharmaceuticals specified by their functions and mechanisms

. . Drugs for receptor antagonism (*)

. . . beta-blockers

. . . Histamine H2 blocker

. . . Histamine H1 blocker

. . Anti-platelet activation factors (PAF) medicinal

. . Calcium antagonists

ZC51

ZC52

ZC54

ZC55

. Pharmaceuticals specified by treatment objects

. . Drugs for geriatric diseases

. . Medicines specified by symptoms or diseases (*)

. . . Drugs to treat acquired immuno-deficiency syndrome (AIDS)

ZC61

ZC62

ZC63

ZC64

ZC65

. . Drugs for animals

. . . Udder-inflammation drugs

. . . Milk-inducing drugs

. . . Drugs for animal coccidiosis

. . . Drugs for poikilothermic animals

ZC71

ZC72

ZC75

ZC78

ZC80

. Pharmaceuticals for physical therapy

. . Pharmaceuticals for moxibusion therapy

. Pharmaceuticals with synergy

. Analysis or detection reagents

. Others or indefinite article (*)

4C084	MEDICINES THAT CONTAIN PROTEIN LIPID ENZYMES AND OTHER MEDICINES
	A61K38/00 -38/58;41/00-45/08;48/00;50/00,100;51/00,100;51/02,100;51/04,100;51/04,310;51/06,100;51/08,100;51/10,100;51/12,100